NICOTROL NS Rx
Generic Name and Formulations:
Nicotine 0.5mg/spray; aqueous nasal spray.
McNeil Consumer Healthcare
Indications for NICOTROL NS:
Adjunct in smoking cessation therapy.
Do not sniff, swallow, or inhale. Individualize. Usually 1–2 doses/hour; max 5 doses/hour, 40 doses/day for up to 3 months; may discontinue abruptly or taper.
Concurrent smoking or other nicotine products.
Avoid immediately post-MI, in arrhythmias, or severe or worsening angina pectoris. Hypertension. Vasospastic or coronary heart disease. Hepatic or severe renal impairment. Hyperthyroidism. Pheochromocytoma. Diabetes. Peptic ulcer disease. Elderly. Low doses may be toxic to children and pets. Nasal Spray not recommended in chronic nasal disorders. Pregnancy (Cat.D), labor & delivery: not recommended (attempt nondrug treatment first). Nursing mothers.
Nasal Spray antagonized by nasal vasoconstrictors. Smoking cessation potentiates theophylline, insulin, β-blockers, pentazocine, oxazepam, tricyclic antidepressants (eg, imipramine), caffeine, acetaminophen, adrenergic antagonists (eg, prazosin, labetalol), others. Smoking cessation antagonizes adrenergic agonists (eg, isoproterenol, phenylephrine), others.
Local irritation, GI upset, headache, dizziness, palpitations, hypertension.
Inhaler 42 cartridges—1 (w. inhaler and case); Nasal Spray 10mL (200 sprays)—1 (w. metered spray pump)
Neurology Advisor Articles
- Higher Levels of Cholesterol May Protect Men From Parkinson Disease
- Ajovy Injection Approved for Migraine Prevention in Adults
- Chronic Pain May Be Contributor to Suicide
- FDA Approves Tiglutik for the Treatment of Amyotrophic Lateral Sclerosis
- Natalizumab Improves Cognitive Function in Multiple Sclerosis
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- New 15-Item Dyspnea-ALS-Score Assesses Dyspnea in ALS
- CDC: About One in Five U.S. Adults Have Chronic Pain
- Fingolimod Cuts Multiple Sclerosis Relapses in Pediatric Patients
- Gains in Insurance Coverage Seen for Lesbian, Gay, Bisexual Adults
- Brivaracetam Effective for Reducing Seizures in Patients with Epileptic Encephalopathies